Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-2: Neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy for resectable pancreatic cancer
NL-OMON55463Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FOLFIRINOX, gemcitabine in pancreatic adenocarcinoma (PDAC), pancreatic cancer (PC), sponsored by Erasmus MC. Started Jun 2018; status: recruiting.
02
Drugs
FOLFIRINOXgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON55463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55463.